Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03142919 · ClinicalTrials.gov registry record · Phase 1

Lipopolysaccharide (LPS) Challenge in Depression

A Phase 1 study, sponsored by Laureate Institute for Brain Research.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target

NCT03142919: Completed Phase 1 study, sponsored by Laureate Institute for Brain Research.

NCT03142919 is a Phase 1 study that has completed, run by Laureate Institute for Brain Research. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03142919, a Phase 1 study, has completed, sponsored by Laureate Institute for Brain Research.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target

Study Summary

LPS Challenge in Individuals with Major Depressive Disorder

Primary Outcome

The SHAPS is a 14-item self-administered questionnaire, with each item scored from 1-4 (strongly agree through strongly disagree; range 14-56), with higher scores indicating greater anticipatory, not consummatory, anhedonia. Disagreement (i.e. score of 3 or 4) on at least three items is defined as indicating clinically significant anhedonia.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Lipopolysaccharide

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2017-09-07
Est. Completion 2020-12-01
Phase Phase 1

What the finished NCT03142919 record still lists

NCT03142919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03142919 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03142919 about?

NCT03142919 is a clinical study titled "Lipopolysaccharide (LPS) Challenge in Depression". LPS Challenge in Individuals with Major Depressive Disorder

What is the current status of trial NCT03142919?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2017-09-07. Estimated completion is 2020-12-01.

What interventions are being tested in trial NCT03142919?

The interventions under investigation include: Placebo (BIOLOGICAL), Lipopolysaccharide (BIOLOGICAL).

Who is sponsoring clinical trial NCT03142919?

This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03142919's enrollment target sits among peer trials

64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03142919, the US trial registry maintained by the National Library of Medicine. NCT03142919 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.